Sanofi 2016 IR
The report highlights Sanofi's strategic roadmap for sustainable value creation, focusing on its first integrated approach in 2016. The company achieved solid financial performance with net sales of –33.8 billion, while advancing its CSR strategy across four pillars: ethics and transparency, access to healthcare, community engagement, and environmental challenges. Key achievements include the launch of Dengvaxia, the first dengue vaccine, and the establishment of Onduo, a joint venture for diabetes management. Sanofi also made progress in reducing its environmental footprint, achieving a 19.4% reduction in Scope 1 and 2 CO2 emissions compared to 2010.
Company: Sanofi
Sector: Health Care
Country: France
Year: 2016
Type: IR
Pages: 64
Back to company
Sanofi
Integrated Report
The report highlights Sanofi's strategic roadmap for sustainable value creation, focusing on its first integrated approach in 2016. The company achieved solid financial performance with net sales of –33.8 billion, while advancing its CSR strategy across four pillars: ethics and transparency, access to healthcare, community engagement, and environmental challenges. Key achievements include the launch of Dengvaxia, the first dengue vaccine, and the establishment of Onduo, a joint venture for diabetes management. Sanofi also made progress in reducing its environmental footprint, achieving a 19.4% reduction in Scope 1 and 2 CO2 emissions compared to 2010.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2016
Reporting Period
Jan 1, 2016 - Dec 31, 2016
Fiscal Year
2016
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 3:
Water Consumption
Women on Board
Employees